XOMA Royalty carries a perfect 4-for-4 earnings beat streak and excellent returns (34% ROE, 70% margins), but negative free cash flow, a failed Rule of 40, and a price already well past the analyst target temper the case in a binary biotech setup.
Thesis pillars
- Binary Biotech Speculative Risk→Stable
- Excellent Roe Strong Margins→Stable
- Negative Fcf Rule Of 40 Fail→Stable
- +2 more pillars — see the Why tab for full reasoning
XOMA Royalty Corporation (XOMA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $45.00 — A.R:R is negative (-2.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (-2.3% away).
XOMA Royalty Corporation is a royalty aggregator that buys the rights to future milestone and royalty payments from biotech drug developers in exchange for non-dilutive, non-recourse capital, holding economic interests in more than 120 commercial and pre-commercial assets. Its... Read more
Sell if holding. Analyst target reached at $45.00 — A.R:R is negative (-2.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (-2.3% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About XOMA Royalty Corporation
About XOMA Royalty Corporation
XOMA Royalty holds economic interests in more than 120 commercial and pre-commercial drug programs, anchored by royalty and milestone streams from seven commercial-stage assets that together generated $50.5 million in total cash receipts in 2025. Roche's VABYSMO, a retinal-disease antibody on which XOMA holds a 0.5% royalty, was the single largest contributor at $22.5 million, while OJEMDA (Day One Biopharmaceuticals) added $14.1 million in combined royalties and milestones.
XOMA generates revenue entirely through non-dilutive royalty and milestone purchase agreements rather than by developing or selling drugs itself: it pays an upfront sum to a biotech sponsor or a legacy licensor in exchange for a share of that sponsor's future royalties, regulatory milestones, and commercial payments, leaving substantially all R&D and commercialization costs and risk with the drug's actual developer. Beyond direct royalty purchases, XOMA has also acquired entire companies -- Kinnate, LAVA, and Pulmokine among them -- through tender offers to obtain their partnered-program royalty rights and any unpartnered pipeline assets, which it then seeks to sell or out-license; it divested five unpartnered Kinnate assets in 2025. The company also holds a Takeda Revenue Share Agreement entitling it to portions of milestone and royalty payments Takeda may receive across a diversified basket of nine development-stage assets, spreading its exposure across therapeutic areas including oncology, autoimmune disease, neurology, and rare disease rather than concentrating it in one program.
Show full overview
XOMA's own risk factors flag that its acquired royalty and milestone streams carry counterparty credit risk if a licensor or licensee defaults or enters bankruptcy, a risk realized in 2024 when Talphera's DSUVIA program produced a $7.9 million credit loss on purchased receivables after the drug was pulled from the commercial market; XOMA collected just $28,000 from that asset in 2025. That history underscores the concentration risk embedded in VABYSMO, which alone accounted for roughly 45% of XOMA's $50.5 million in 2025 total cash receipts, a single Roche royalty stream large enough that any adverse change in VABYSMO's net sales would disproportionately affect XOMA's near-term cash flow versus its more diversified late-stage and early-stage holdings.
See also: Healthcare · Biotechnology
From XOMA Royalty Corporation's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMcounterpartyRoche (VABYSMO)10-K Item 1: 'We are eligible to receive commercial payments from Roche consisting of 0.5% of future net sales of VABYSMO for a ten-year period following the first commercial sales in each applicable jurisdiction. ... we received commercial payments totaling $22.5 million in 2025 and $16.9 million in 2024.'
Material Events(8-K, last 90d)
- 2026-05-22Item 5.02LOWAt the May 21, 2026 annual meeting, stockholders approved an amendment increasing shares under the 2010 Long Term Incentive Plan by 425,000 and adopted a 2026 Employee Stock Purchase Plan. No officer or director departure or appointment involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $45.00 — A.R:R is negative (-2.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (-2.3% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $43.82. Score 5.7/10, moderate confidence.
Take-profit target: $44.29 (-1.6% upside). Prior stop was $43.82. Stop-loss: $43.82.
Analyst target reached - limited upside remaining; Near 52-week high (-2.3% away); Leverage penalty (D/E 1.1): -0.5.
XOMA Royalty Corporation trades at a P/E of 27.9 (forward 20.5). TrendMatrix value score: 5.8/10. Verdict: Sell.
9 analysts cover XOMA with a consensus score of 3.9/5. Average price target: $39.
What does XOMA Royalty Corporation do?XOMA Royalty Corporation is a royalty aggregator that buys the rights to future milestone and royalty payments from...
XOMA Royalty Corporation is a royalty aggregator that buys the rights to future milestone and royalty payments from biotech drug developers in exchange for non-dilutive, non-recourse capital, holding economic interests in more than 120 commercial and pre-commercial assets. Its portfolio generated $50.5 million in total cash receipts in 2025, with Roche's VABYSMO alone contributing $22.5 million of that total, while XOMA also acquires whole companies (Kinnate, LAVA, Pulmokine) to obtain additional royalty streams.